Role of nitric oxide in myocardial preconditioning

Buddhadeb Dawn, Roberto Bolli

Research output: Contribution to journalArticle

Abstract

Ischemic preconditioning (PC) is a polygenic defensive cellular adaptive phenomenon whereby brief ischemic stimuli render the heart resistant to subsequent similar stress. The late phase of ischemic PC lasts for three to four days, protects against both myocardial stunning and infarction, and thus has considerable clinical relevance. Diverse signaling molecules released by a sublethal ischemic stress initiate a complex signal transduction cascade that modulates the expression of cardioprotective genes. Nitric oxide (NO), generated by the endothelial NO synthase (NOS) and acting via the formation of reactive oxygen species, activates the ε isoform of protein kinase C (PKC), which activates the Src family of protein tyrosine kinases (Src and Lck) and transcription factors (nuclear factor-κB, and possibly others), with resultant upregulation of the inducible NOS (iNOS) gene and protein expression, iNOS, and other cardioprotective proteins, including cyclooxygenase-2 and aldose reductase, confer resistance to subsequent ischemic stress. This delayed protection can also be mimicked, in the absence of ischemia, by administering NO-releasing agents, a situation that can be potentially exploited for cardioprotection in clinical situations. Identification of this novel bifunctional (trigger and mediator) role played by NO in cardiac protection, not only advances the knowledge regarding its signaling functions, but also offers a potential therapeutic strategy for patients with coronary artery disease. The purpose of this review is to summarize the current evidence in support of this critical role played by NO in ischemic PC.

Original languageEnglish (US)
Pages (from-to)18-41
Number of pages24
JournalAnnals of the New York Academy of Sciences
Volume962
StatePublished - 2002
Externally publishedYes

Fingerprint

Myocardial Ischemic Preconditioning
Ischemic Preconditioning
Nitric Oxide
src-Family Kinases
Myocardial Stunning
Gene Expression
Aldehyde Reductase
Signal transduction
Nitric Oxide Synthase Type III
Cyclooxygenase 2
Nitric Oxide Synthase
Protein Kinase C
Coronary Artery Disease
Reactive Oxygen Species
Signal Transduction
Protein Isoforms
Proteins
Transcription Factors
Up-Regulation
Ischemia

Keywords

  • Ischemic preconditioning
  • Nitric oxide
  • Nuclear factor-κB
  • Protein kinase C
  • Protein tyrosine kinases

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Role of nitric oxide in myocardial preconditioning. / Dawn, Buddhadeb; Bolli, Roberto.

In: Annals of the New York Academy of Sciences, Vol. 962, 2002, p. 18-41.

Research output: Contribution to journalArticle

Dawn, Buddhadeb ; Bolli, Roberto. / Role of nitric oxide in myocardial preconditioning. In: Annals of the New York Academy of Sciences. 2002 ; Vol. 962. pp. 18-41.
@article{72da24d32b9c490babd58199e5124e4f,
title = "Role of nitric oxide in myocardial preconditioning",
abstract = "Ischemic preconditioning (PC) is a polygenic defensive cellular adaptive phenomenon whereby brief ischemic stimuli render the heart resistant to subsequent similar stress. The late phase of ischemic PC lasts for three to four days, protects against both myocardial stunning and infarction, and thus has considerable clinical relevance. Diverse signaling molecules released by a sublethal ischemic stress initiate a complex signal transduction cascade that modulates the expression of cardioprotective genes. Nitric oxide (NO), generated by the endothelial NO synthase (NOS) and acting via the formation of reactive oxygen species, activates the ε isoform of protein kinase C (PKC), which activates the Src family of protein tyrosine kinases (Src and Lck) and transcription factors (nuclear factor-κB, and possibly others), with resultant upregulation of the inducible NOS (iNOS) gene and protein expression, iNOS, and other cardioprotective proteins, including cyclooxygenase-2 and aldose reductase, confer resistance to subsequent ischemic stress. This delayed protection can also be mimicked, in the absence of ischemia, by administering NO-releasing agents, a situation that can be potentially exploited for cardioprotection in clinical situations. Identification of this novel bifunctional (trigger and mediator) role played by NO in cardiac protection, not only advances the knowledge regarding its signaling functions, but also offers a potential therapeutic strategy for patients with coronary artery disease. The purpose of this review is to summarize the current evidence in support of this critical role played by NO in ischemic PC.",
keywords = "Ischemic preconditioning, Nitric oxide, Nuclear factor-κB, Protein kinase C, Protein tyrosine kinases",
author = "Buddhadeb Dawn and Roberto Bolli",
year = "2002",
language = "English (US)",
volume = "962",
pages = "18--41",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Role of nitric oxide in myocardial preconditioning

AU - Dawn, Buddhadeb

AU - Bolli, Roberto

PY - 2002

Y1 - 2002

N2 - Ischemic preconditioning (PC) is a polygenic defensive cellular adaptive phenomenon whereby brief ischemic stimuli render the heart resistant to subsequent similar stress. The late phase of ischemic PC lasts for three to four days, protects against both myocardial stunning and infarction, and thus has considerable clinical relevance. Diverse signaling molecules released by a sublethal ischemic stress initiate a complex signal transduction cascade that modulates the expression of cardioprotective genes. Nitric oxide (NO), generated by the endothelial NO synthase (NOS) and acting via the formation of reactive oxygen species, activates the ε isoform of protein kinase C (PKC), which activates the Src family of protein tyrosine kinases (Src and Lck) and transcription factors (nuclear factor-κB, and possibly others), with resultant upregulation of the inducible NOS (iNOS) gene and protein expression, iNOS, and other cardioprotective proteins, including cyclooxygenase-2 and aldose reductase, confer resistance to subsequent ischemic stress. This delayed protection can also be mimicked, in the absence of ischemia, by administering NO-releasing agents, a situation that can be potentially exploited for cardioprotection in clinical situations. Identification of this novel bifunctional (trigger and mediator) role played by NO in cardiac protection, not only advances the knowledge regarding its signaling functions, but also offers a potential therapeutic strategy for patients with coronary artery disease. The purpose of this review is to summarize the current evidence in support of this critical role played by NO in ischemic PC.

AB - Ischemic preconditioning (PC) is a polygenic defensive cellular adaptive phenomenon whereby brief ischemic stimuli render the heart resistant to subsequent similar stress. The late phase of ischemic PC lasts for three to four days, protects against both myocardial stunning and infarction, and thus has considerable clinical relevance. Diverse signaling molecules released by a sublethal ischemic stress initiate a complex signal transduction cascade that modulates the expression of cardioprotective genes. Nitric oxide (NO), generated by the endothelial NO synthase (NOS) and acting via the formation of reactive oxygen species, activates the ε isoform of protein kinase C (PKC), which activates the Src family of protein tyrosine kinases (Src and Lck) and transcription factors (nuclear factor-κB, and possibly others), with resultant upregulation of the inducible NOS (iNOS) gene and protein expression, iNOS, and other cardioprotective proteins, including cyclooxygenase-2 and aldose reductase, confer resistance to subsequent ischemic stress. This delayed protection can also be mimicked, in the absence of ischemia, by administering NO-releasing agents, a situation that can be potentially exploited for cardioprotection in clinical situations. Identification of this novel bifunctional (trigger and mediator) role played by NO in cardiac protection, not only advances the knowledge regarding its signaling functions, but also offers a potential therapeutic strategy for patients with coronary artery disease. The purpose of this review is to summarize the current evidence in support of this critical role played by NO in ischemic PC.

KW - Ischemic preconditioning

KW - Nitric oxide

KW - Nuclear factor-κB

KW - Protein kinase C

KW - Protein tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=0036268389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036268389&partnerID=8YFLogxK

M3 - Article

VL - 962

SP - 18

EP - 41

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -